• Berbamine hydrochloride: Assay Workflow Guide

  2026-08-12

  Build reproducible cytotoxicity, signaling, and ferroptosis-resistance assays with Berbamine hydrochloride while keeping solvent, timing, and cell-context variables under control. The workflow connects practical NF-κB and STAT3 pathway testing with the METTL16–SENP3–LTF ferroptosis framework in hepatocellular carcinoma research.

• CBD, Orofacial Pain, and Affective Recovery

  2026-08-11

  A 2026 mouse study shows that cannabidiol (CBD) can reduce both inflammatory orofacial pain and pain-associated emotional and cognitive deficits. Its most important contribution is a mechanistic framework connecting peripheral CB2 signaling, central CB1 pathways, endocannabinoid changes, inflammation, oxidative stress, and serotonin dynamics.

• KU-60019: ATM Kinase Inhibitor Workflows

  2026-08-11

  KU-60019 enables selective ATM kinase inhibition for DNA damage response studies, glioma radiosensitization, and migration assays. Its high kinase selectivity also supports exploratory combination studies that connect repair signaling with metabolic vulnerability while keeping model-specific limitations visible.

• Mdivi-1 Workflow for DRP1 and Mitochondrial Fission

  2026-08-10

  Mdivi-1 provides a practical chemical probe for separating mitochondrial fission from downstream apoptosis and stress signaling. This workflow connects ECM remodeling, mitochondrial dynamics, apoptosis assays, and ischemic-retina models while emphasizing controls that improve interpretation and reproducibility.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-08-09

  The reference study identifies CD44 as a metabolic dependency of IDH-mutant leukemia, linking R-2HG-driven CD44 induction to pentose phosphate pathway activation, glycolysis suppression, and sustained NADPH production. Its findings support combination strategies that pair mutant-IDH inhibition with CD44-directed perturbation while highlighting the need to address resistance in acute myeloid leukemia.

• DiD Maps Cell Trajectories in Diabetic Periodontitis

  2026-08-08

  DiD (DiDC 18 (5)) provides long-wavelength red membrane labeling for tracking macrophage behavior and cell interactions in complex diabetic periodontitis models. This article explains how to use the probe as a spatial assay layer alongside the ROS–mitochondria–inflammation framework, while avoiding overinterpretation of membrane fluorescence.

• Mechanisms of Spiroplasma eriocheiris Entry into Drosophila

  2026-08-07

  This study elucidates how Spiroplasma eriocheiris invades Drosophila Schneider 2 cells, revealing reliance on clathrin-mediated endocytosis and macropinocytosis rather than caveolae-dependent pathways. The work advances understanding of host-pathogen interactions in invertebrate systems, offering mechanistic insights that may inform future research on cellular invasion and innate immune response.

• Topotecan as a Topoisomerase I Inhibitor: Mechanistic Insigh

  2026-08-06

  The reference review details the pharmacology, clinical evaluation, and mechanistic innovation of topotecan, a water-soluble topoisomerase I inhibitor. Its distinct mechanism, clinical efficacy in refractory cancers, and comparison to established regimens like cyclophosphamide-based therapies inform protocol development and combination strategies in translational oncology.

• Maraviroc (UK-427857): Protocols for CCR5-Targeted Research

  2026-08-06

  Maraviroc (UK-427857) is a gold-standard CCR5 antagonist, enabling precise dissection of HIV-1 entry, neuroinflammation modulation, and now, extracellular vesicle-driven inflammatory pathways in rheumatoid arthritis. This guide distills recent experimental breakthroughs—especially in RA models—into actionable protocols and troubleshooting strategies, maximizing the reliability of Maraviroc-based assays.

• Cy3-dCTP: Direct Enzymatic DNA Labeling for High-Fidelity As

  2026-08-05

  Cyanine 3-dCTP empowers direct, high-efficiency labeling of DNA and cDNA, delivering robust signal and protocol versatility across PCR, Nick Translation, and in situ hybridization. This guide details experimental workflows, troubleshooting strategies, and the latest advances in enzymatic synthesis that elevate Cy3-dCTP’s value in genomic research.

• Redefining mRNA Synthesis: Strategic Leverage for Translatio

  2026-08-05

  Explore how mechanistic advances in ARCA capping, immune-evasive nucleotide modifications, and workflow integration—embodied by the HyperScribe™ All in One mRNA Synthesis Kit Plus 1—are driving a new era of translational mRNA research. This article provides deep mechanistic insight, evidence-backed best practices, and strategic guidance for researchers aiming to accelerate RNA vaccine development, reduce immunogenicity, and achieve robust in vitro translation using next-generation mRNA synthesis platforms.

• (+)-Bicuculline: Protocol Parameters and Workflow for GABAA

  2026-08-04

  (+)-Bicuculline is a classical GABAA receptor antagonist used to dissect inhibitory neurotransmission and study synaptic NMDA receptor signaling in neuroscience research. It is unsuitable for diagnostic or therapeutic use and requires precise attention to solubility, storage, and workflow handling for reproducible results.

• Hoechst 33342 Nuclear Stain: Advanced Workflows in Fibroblas

  2026-08-04

  Hoechst 33342 Solution (1 mg/mL) empowers researchers to achieve precise, low-toxicity nuclear staining in both live and fixed dermal fibroblasts, streamlining senescence and mitochondrial quality assays. Recent advances highlight its pivotal role in high-content imaging and flow cytometry for anti-aging research. Discover protocol enhancements and troubleshooting strategies for robust, reproducible results.

• Gepotidacin in Antibacterial Research: Protocols and Pitfall

  2026-08-03

  Gepotidacin (GSK2140944) empowers scientists tackling antibiotic resistance with a novel, mechanism-driven approach to bacterial DNA replication inhibition. This article translates recent pharmacokinetic discoveries and peer-reviewed protocols into actionable workflows, troubleshooting, and comparative insights for advanced antibacterial research.

• Palonosetron Hydrochloride in CINV: Pharmacologic Advances a

  2026-08-03

  The reference study by Ruhlmann & Herrstedt offers a detailed comparative analysis of palonosetron hydrochloride, a next-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting (CINV). The paper highlights palonosetron's prolonged half-life and allosteric receptor binding as key innovations, translating into improved efficacy for both acute and delayed CINV. These findings inform clinical strategies and experimental design in supportive oncology research.

8041 records 3/537 page Previous Next 12345 下5页 Last page